CytomX Therapeutics CTMX Cash Flow Statement (2014-2026)

NASDAQ CTMX
$3.61 -0.08 (-2.04%)
As of: Sep 4, 2026 · 12:49 PM EDT
Reported Financials

CytomX Therapeutics Quarterly Cash Flow Statement

Periods 48 quarters
Latest Jun 2026

CytomX Therapeutics reported cash from operations of -$18.07M and free cash flow of -$18.07M for the quarter ended Jun 2026, down 14.7% year over year. This cash flow statement covers 48 quarters of results from Sep 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-30.98M-34.82M-31.98M-29.50M-29.06M-8.78M-3.31M-1.09M2.99M0.84M13.79M-6.53M5.74M18.88M23.52M-0.15M-14.23M-22.67M-18.25M-20.67M
Share-based CompensationStock Comp.
11.51M3.54M14.31M14.43M14.26M2.57M14.13M13.82M13.29M2.55M14.31M14.51M14.57M1.88M16.78M16.41M16.18M1.48M18.88M19.47M
Deferred Taxes
Cash from OperationsCash from Ops.
-29.70M-31.19M-41.31M-34.24M-33.84M-1.39M9.35M-25.18M-18.24M-21.96M-26.05M-19.55M-20.73M-19.91M-21.04M-15.75M-15.55M-23.24M-25.55M-18.07M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-0.01M0.01M0.02M0.02M0.01M0.01M1.53M1.73M1.93M2.23M1.87M1.44M1.22M0.79M0.45M0.40M0.64M0.72M0.73M1.43M
Depreciation & Amortization (CF)Dep. & Amort.
Change in Working Capital
Change in ReceivablesChange Receivables
-0.04M-0.10M0.23M0.06M0.70M34.21M-34.90M0.81M0.52M1.01M9.74M-10.40M0.58M-0.25M-1.15M-0.09M-0.24M0.38M-1.37M36.85M
Change in Account PayablesChange Payables
-0.18M1.22M-1.06M0.22M3.29M-2.37M-0.62M-1.16M0.68M-0.33M0.58M-1.43M0.81M-0.26M-0.80M-0.05M0.42M0.66M0.07M0.57M
Change in Accured ExpensesChange Accured Exp.
5.01M8.11M-4.18M-0.30M-1.41M-3.89M-7.36M-3.12M2.01M1.42M-4.43M-1.67M2.03M-5.55M-2.11M-1.10M-0.33M0.49M-3.60M3.34M
Other Working Capital ChangesOther WC Changes
-8.30M-10.34M-8.03M-11.84M-9.44M45.86M-17.41M-22.76M-24.50M-24.34M-28.94M-22.89M-30.86M-35.56M-44.62M-17.15M-4.38M0.55M-9.61M35.84M
Investing Activities
Capital ExpendituresCapex
0.27M0.24M0.74M0.41M0.41M0.18M0.05M0.52M0.01M0.27M0.12M0.10M0.02M0.08M0.12M0.03M-0.13M0.20M
Change in Acquisitions & DivestmentsChange Acquisitions
10.00M100.00M100.00M50.00M125.00M45.00M115.00M30.50M65.00M50.50M32.50M20.00M30.00M50.00M75.00M
Cash from Investing ActivitiesCash from Investing
9.73M-0.24M-0.74M-0.41M-0.41M99.82M-146.64M26.04M-42.94M12.87M44.88M21.51M18.17M15.13M30.60M-76.36M0.44M-14.42M-192.78M5.95M
Financing Activities
Other financing activitiesOther financing
0.10M0.68M0.01M0.45M0.19M0.32M29.35M0.17M0.26M0.18M0.18M0.25M0.38M5.86M
Cash from Financing ActivitiesCash from Financing
0.10M0.68M0.01M0.45M0.19M0.32M29.67M0.24M0.17M5.10M2.25M93.55M0.25M16.64M234.49M0.51M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
5.18M2.56M4.99M1.15M2.26M1.78M2.39M2.83M4.65M2.61M
Net Equity Issued and RepurchasedNet Equity Issued
0.04M2.07M93.37M16.30M228.35M0.06M
Additional items
Change in Cash
-19.86M-30.75M-42.04M-34.20M-34.26M98.61M-137.29M1.18M-31.51M-8.85M19.01M7.06M-2.56M-2.52M9.55M1.44M-14.86M-21.02M16.16M-11.60M
Free Cash FlowFCF
-29.97M-31.44M-42.05M-34.65M-34.26M-1.57M9.30M-25.70M-18.25M-22.23M-26.16M-19.64M-20.75M-19.99M-21.16M-15.78M-15.42M-23.44M-25.55M-18.07M
Net Cash FlowNCF
-19.86M-30.75M-42.04M-34.20M-34.26M98.61M-137.29M1.18M-31.51M-8.85M19.01M7.06M-2.56M-2.52M9.55M1.44M-14.86M-21.02M16.16M-11.60M